Kenvue (KVUE) faces significant regulatory and reputational headwinds as the Trump administration asserted, without evidence, a definitive link between acetaminophen, the active ingredient in pain reliever Tylenol, and autism during pregnancy. This represents a direct challenge to one of Kenvue's most important revenue drivers within its Self-Care segment, which includes trusted brands such as Tylenol, Motrin, and Benadryl.
The consumer health company, spun off from Johnson & Johnson (JNJ) in 2023, has responded to defend the safety profile of acetaminophen. CEO Kirk Perry personally met with HHS Secretary Robert F. Kennedy Jr. to dispute these claims, while the company emphasizes that "over a decade of rigorous research" shows no credible evidence linking acetaminophen to autism.
